ESMO 2016 header

ESMO 2016 Coverage

First-line Nivolumab Not Superior to Chemo for Stage IV/Recurrent PD-L1+ NSCLC

First-line Nivolumab Not Superior to Chemo for Stage IV/Recurrent PD-L1+ NSCLC

First-line treatment with nivolumab was not superior to investigator's choice of platinum-based doublet chemotherapy for progression-free survival.

Full-dose Neoadjuvant Anthracycline + Ifosfamide Improves OS in High-risk Soft Tissue Sarcoma

Full-dose Neoadjuvant Anthracycline + Ifosfamide Improves OS in High-risk Soft Tissue Sarcoma

Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.

Atezolizumab Improves Overall Survival Versus Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Versus Docetaxel in NSCLC

Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.

Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.

Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.

Durvalumab Shows Encouraging OS Rates in Advanced HNSCC

Durvalumab Shows Encouraging OS Rates in Advanced HNSCC

PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.

Study Explores Efficacy of Fosaprepitant Regimen Among Patients Receiving MEC

Study Explores Efficacy of Fosaprepitant Regimen Among Patients Receiving MEC

A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.

Nivolumab Feasible for Early Stage Resectable NSCLC

Nivolumab Feasible for Early Stage Resectable NSCLC

Study findings suggest that anti-PD1 immunotherapy may have significant activity among patients with early stage NSCLC.

Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer

Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer

Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.

Alisertib May Benefit Some Patients With Neuroendocrine Prostate Cancer

Alisertib May Benefit Some Patients With Neuroendocrine Prostate Cancer

Aurora kinase A inhibition with alisertib monotherapy may benefit a subset of patients with neuroendocrine prostate cancer (NEPC).

Abemaciclib Associated With a Greater Reduction in Ki67 Than Anastrozole in Breast Cancer

Abemaciclib Associated With a Greater Reduction in Ki67 Than Anastrozole in Breast Cancer

Among women with HER2-negative breast cancer, treatment with abemaciclib reduced Ki67 levels more than anastrozole.

Daratumumab Plus Bortezomib and Dex Improves PFS, ORR in Myeloma

Daratumumab Plus Bortezomib and Dex Improves PFS, ORR in Myeloma

Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.

Nivolumab May Be Better Than BSC for Advanced Hepatocellular Carcinoma

Nivolumab May Be Better Than BSC for Advanced Hepatocellular Carcinoma

Second-line treatment with nivolumab was well tolerated and associated with encouraging preliminary activity among patients with hepatocellular carcinoma.

Everolimus + Letrozole Efficacious in ER+, HER2- Advanced Breast Cancer

Everolimus + Letrozole Efficacious in ER+, HER2- Advanced Breast Cancer

Everolimus plus letrozole is efficacious as a first-line treatment regimen for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.

Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

Compared with best supportive care, trabectedin significantly improves progression-free survival among patients with pretreated advanced soft tissue sarcoma.

Adding Evofosfamide to Doxorubicin Fails to Improve OS in Sarcoma

Adding Evofosfamide to Doxorubicin Fails to Improve OS in Sarcoma

Among patients with advanced soft tissue sarcoma, adding evofosfamide to doxorubicin failed to improve overall survival compared with doxorubicin alone.

Ceritinib Active in ALK Inhibitor-naive Patients With ALK+ NSCLC

Ceritinib Active in ALK Inhibitor-naive Patients With ALK+ NSCLC

Ceritinib induced robust whole body responses in anaplastic lymphoma kinase (ALK) inhibitor-naive patients with ALK-rearranged non-small cell lung cancer (NSCLC).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs